Regulatory
FDA Approves First Muscle-Targeted Therapy for Spinal Muscular Atrophy
Scholar Rock’s Isembyld (apitegromab) attacks spinal muscular atrophy from a new direction — the muscle itself — and is designed to layer on top of the nerve-focused drugs that transformed the disease over the past decade.